ApoA-I Infusions and Burden of Ischemic Events after Acute Myocardial Infarction
KEY POINTS: In this prespecified exploratory analysis of the AEGIS-II trial, the authors compare rates… Continue Reading
Featured NewsView All
Apolipoprotein A-I infusions Lowers Risk of Recurrent CV Events in Patients With Baseline LDL-C ≥100 mg/dL
KEY POINTS: In this exploratory analysis of the AEGIS-II randomized control trial, the authors compare… Continue Reading
Improved Accuracy of HF Diagnosis with HFDetect-AI
Key Points: HFDetect-AI significantly improves the accuracy of diagnosing heart failure by predicting left ventricular… Continue Reading
Featured Videos
Featured PodcastsView All
Organizing and Actualizing a Polypharmacy
Dr. Fanikos Speaks at Brigham and Womens’ Hospital
Podcast: Download
Latest Tweets
NewsView All
Pre-Hospital Pulse-Dose Glucocorticoid Did not Reduce Infarct Size in STEMI: PULSE-MI
Key Points: The PULSE-MI trial assessed the effects of pre-hospital pulse-dose glucocorticoid on final infarct… Continue Reading
ECLS-SHOCK: At One Year, ECMO Does Not Reduce Mortality in Acute MI-Related Cardiogenic Shock
Key Points: The 30-day ECLS SHOCK study demonstrated no benefit to up-front ECLS in the… Continue Reading
REC-CAGEFREE I: Drug Coated Balloon Fails To Achieve Non-Inferiority vs DES For De Novo Coronary Lesions
Key Points Drug-eluting stents are the standard of care for percutaneous coronary intervention of de… Continue Reading
Plozasiran Lowered Triglyceride Levels and Pancreatitis in Persistent Chylomicronemia: PALISADE
Key Points: Familial chylomicronemia syndrome (FCS) is a clinically or genetically defined syndrome of extremely… Continue Reading
Bailout GP IIb/IIIa inhibition in AMI with angiographic MVO failed to reduce the primary endpoint infarct size but decreased CMR-derived MVO: The REVERSE-FLOW trial
Key Points: Though primary PCI for coronary obstruction is first-line therapy in acute myocardial infarction… Continue Reading
AZALEA-TIMI 71 Sub-study: Periprocedural Bleeding Risk Very Low and Similar With Long-acting Factor XI Inhibitor Abelacimab vs Rivaroxaban
Key Points: Factor XI inhibitors have the potential to reduce thromboembolic events while minimizing major… Continue Reading
